P2D Bioscience said preclinical testing and numerous scientific publications indicate that PD2007 inhibits dopamine transport in multiple brain regions.
The company said, in addition to its inhibiting activity, PD2007 demonstrates no abuse potential, which is an advantage over other approved dopamine transport inhibitors which are Schedule II drugs of abuse.
Further, PD2007 demonstrates no functionally cardiovascular effects on blood pressure and heart rate unlike other approved dopamine transport inhibitors.
P2D Bioscience plans to raise private equity funding for PD2007 clinical safety and efficacy studies, as well as to support testing of P2D’s proprietary TNF-alpha inhibitors.
P2D’s anti-inflammatory compounds are proprietary drugs that inhibit TNF-alpha synthesis or a ‘chemical switch,’ RAC/GTPase.